Clinical Trial Update: Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the safety and potential therapeutic effects of a single IV infusion of autologous CD34+ cells enriched with allogenic pl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Diseases
• Pearson Syndrome

Drugs mentioned

• Autologous CD34+ cells enriched with allogenic placenta-derived mitochondria

Snippet

Sponsor: Minovia Therapeutics Ltd. | Conditions: Mitochondrial Diseases, Pearson Syndrome | Phase 2 | Status: RECRUITING